LambdaGuide Enters Prospective Testing in Cystoscopic Anatomy Measurement
A new prospective study is evaluating whether the LambdaGuide System can reliably capture point-to-point measurements of visible genitourinary anatomy during cystoscopic procedures in adult men. The trial is not designed to alter care or direct treatment decisions; its purpose is narrower and more technical, centered on whether the system can function inside a real procedural workflow without disrupting standard endoscopy.
The study is observational, case-only, and prospective. Enrollment is estimated at 10 participants, with recruitment open in Boston, Massachusetts, at PINE, the Prostate Institution of New England. Adult males aged 22 years and older may participate if they are undergoing a non-emergency cystoscopic procedure or, when specifically permitted by the protocol, if they are healthy adult volunteers. Participation depends on informed consent and on the investigator’s judgment that the procedure remains medically appropriate.
How the Device Is Intended to Work During Cystoscopy
LambdaGuide is described as an investigational optical measurement system that integrates with a compatible cystoscope. During the procedure, clinicians will set up the camera module, complete calibration using an approved target, and attempt to measure visible structures within the urinary tract. The intended measurement targets include openings or narrowing, urethral strictures, distances between anatomic landmarks, lesions, stones, foreign bodies, and implant-related structures.
In practical terms, the system is trying to solve a familiar endoscopic problem: visualization alone does not always provide a reproducible sense of scale. Cystoscopy can reveal a lesion or narrowing, but the clinical eye is still left estimating size, distance, and geometry. An optical measurement tool could, if it works consistently, create a more standardized way to document anatomy that is directly seen through the scope.
A single sentence captures the study’s central bet: the device must measure visible anatomy without changing how the procedure is otherwise performed.
Feasibility Comes Before Any Claim of Clinical Value
The primary performance endpoint is procedure-level clinical measurement feasibility. An evaluable procedure passes if at least one successful point-to-point measurement is obtained. That endpoint is intentionally modest, and it should be read as an engineering and workflow benchmark rather than a claim of diagnostic superiority.
This matters because the first challenge for any endoscopic measurement platform is not whether it can theoretically calculate a distance. The real test is whether it can do so inside a live procedure, after calibration, with acceptable image capture, valid point selection, and enough procedural stability to complete the measurement. If the device cannot clear those basic hurdles, higher-level questions about accuracy or clinical utility never become relevant.
Secondary outcomes break the workflow into its component parts: calibration success, camera deployment and expected image display, spatial capture success, valid point-selection success, successful measurement completion, calibration and measurement time, procedure interference, and user acceptance. Those measures are descriptive, but they are clinically important because they map the boundary between a useful endoscopic adjunct and an instrument that slows or complicates care.
Safety Monitoring Extends 30 Days After the Procedure
Safety evaluation runs from the procedure date through 30 days afterward, with a permitted window of plus or minus 5 days. Investigators will document adverse events by severity, seriousness, and relationship to the device or the procedure. Device deficiencies and malfunctions will also be recorded.
For a study like this, safety is not only about adverse events in the narrow sense. Procedural interference, failed deployment, calibration problems, and software-related delays can become meaningful harms if they extend the case, affect comfort, or complicate standard cystoscopic work. The protocol therefore treats usability and safety as overlapping domains, which is appropriate for an early device evaluation in a procedural specialty.
One practical issue looms over the entire study: if the system cannot be integrated smoothly into routine cystoscopy, its promise will remain theoretical even if the measurements appear technically sound.
Why the Trial Design Is Deliberately Conservative
The protocol does not allow LambdaGuide measurements to guide diagnosis, treatment selection, or any modification of standard clinical care. Optional comparisons with known-dimension references may be performed, but only for descriptive purposes; they are not intended to establish measurement accuracy. That structure keeps the study anchored to feasibility and performance rather than effectiveness.
This conservative design makes sense for a first-in-type procedural platform. In genitourinary endoscopy, visible anatomy is often variable, tissue planes are dynamic, and the relevant structures may be small or irregularly shaped. A measurement tool must prove that it can work under those conditions before anyone can ask whether it improves decisions around strictures, lesions, stones, or implants.
The inclusion and exclusion criteria reinforce that point. Participants must be medically suitable for the procedure, must be able to consent, and must undergo a cystoscopic exam expected to provide enough visualization for an attempted measurement. Exclusion criteria remove situations in which participation would interfere with care, in which a compatible cystoscope cannot be used, or in which local anesthetic allergy or other procedural constraints would make the study inappropriate.
What the Study Can and Cannot Establish
This trial can show whether an optical measurement system can be deployed in a procedural setting, calibrated, aimed at valid points, and used to capture point-to-point distances during cystoscopy. It can also show whether clinicians find the workflow acceptable and whether any safety signal emerges over short-term follow-up.
It cannot show that the device improves outcomes, changes management, or outperforms conventional assessment. It also cannot prove measurement accuracy in the sense of a validated reference standard, because any comparative work is limited to descriptive observation. With only an estimated 10 participants, the study is best viewed as an early feasibility check rather than a definitive device validation program.
Still, the clinical question is concrete. Urologists routinely inspect anatomy through the cystoscope, yet scale remains an imprecise part of the exam. If LambdaGuide can consistently convert visual inspection into reproducible measurements without disrupting the procedure, it could become a useful adjunct for documenting anatomy in settings where size and distance matter. If it cannot, the data will likely point to the limits of optical measurement inside a live endoscopic workflow rather than to any broader failure of the concept itself.
The study’s first real answer will come from whether at least one measurable procedure can be completed as planned. Everything else depends on that initial demonstration.